The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
出版年份 2016 全文链接
标题
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
作者
关键词
-
出版物
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume 31, Issue 3, Pages 507-517
出版商
Wiley
发表日期
2016-10-22
DOI
10.1111/jdv.14015
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
- (2016) Christopher J Edwards et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data
- (2015) M.K.A. Basra et al. DERMATOLOGY
- Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
- (2015) A. Kavanaugh et al. JOURNAL OF RHEUMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
- (2015) Miguel Perez-Aso et al. ARTHRITIS RESEARCH & THERAPY
- Treatment of Nail Psoriasis
- (2015) Jeffrey J. Crowley et al. JAMA Dermatology
- Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
- (2014) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
- (2014) P.H. Schafer et al. CELLULAR SIGNALLING
- Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
- (2012) Peter Schafer BIOCHEMICAL PHARMACOLOGY
- A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis
- (2012) J.P. Ortonne et al. BRITISH JOURNAL OF DERMATOLOGY
- The roles of cells and cytokines in the pathogenesis of psoriasis
- (2012) Susana Coimbra et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- The concept of psoriasis as a systemic inflammation: implications for disease management
- (2012) K. Reich JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population
- (2008) Eric Q. Wu et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis
- (2008) R SARACENO et al. PHARMACOLOGICAL RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started